Photo of Maria Baggstrom

View Scopus Profile

Maria Baggstrom

Associate Professor of Medicine

    • 979 Citations
    20032020

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    My primary research interest is to develop and conduct phase I and II clinical trials with novel agents for patients with newly diagnosed or relapsed lung cancer. I am also interested in clinical trial methodology and medical education.

    Areas of Clinical Interest

    Thoracic oncology, lung cancer

    Fingerprint Dive into the research topics where Maria Baggstrom is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 15 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output

    • 979 Citations
    • 31 Article
    • 3 Letter
    • 1 Review article

    Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy

    Arnold, S. M., Chansky, K., Baggstrom, M. Q., Thompson, M. A., Sanborn, R. E., Villano, J. L., Waqar, S. N., Hamm, J., Leggas, M., Willis, M., Rosales, J. & Crowley, J. J., Jan 1 2020, (Accepted/In press) In : Clinical Lung Cancer.

    Research output: Contribution to journal › Article

    • Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

    Stinchcombe, T. E., Jänne, P. A., Wang, X., Bertino, E. M., Weiss, J., Bazhenova, L., Gu, L., Lau, C., Paweletz, C., Jaslowski, A., Gerstner, G. J., Baggstrom, M. Q., Graziano, S., Bearden, J. & Vokes, E. E., Oct 2019, In : JAMA oncology. 5, 10, p. 1448-1455 8 p.

    Research output: Contribution to journal › Article

    • 9 Scopus citations

    Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

    Sequist, L. V., Gray, J. E., Harb, W. A., Lopez-Chavez, A., Doebele, R. C., Modiano, M. R., Jackman, D. M., Baggstrom, M. Q., Atmaca, A., Felip, E., Provencio, M., Cobo, M., Adiwijaya, B., Kuesters, G., Kamoun, W. S., Andreas, K., Pipas, J. M., Santillana, S., Cho, B. C., Park, K. & 1 others, Shepherd, F. A., Jan 1 2019, In : Oncologist. 24, 8, p. 1095-1102 8 p.

    Research output: Contribution to journal › Article

    • 3 Scopus citations

    Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

    Baggstrom, M. Q., Socinski, M. A., Wang, X. F., Gu, L., Stinchcombe, T. E., Edelman, M. J., Baker, S., Feliciano, J., Novotny, P., Hahn, O., Crawford, J. A. & Vokes, E. E., May 2017, In : Journal of Thoracic Oncology. 12, 5, p. 843-849 7 p.

    Research output: Contribution to journal › Article

    Open Access
    • 12 Scopus citations

    Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)

    Arnold, S. M., Chansky, K., Leggas, M., Thompson, M. A., Villano, J. L., Hamm, J., Sanborn, R. E., Weiss, G. J., Chatta, G. & Baggstrom, M. Q., Oct 1 2017, In : Investigational New Drugs. 35, 5, p. 608-615 8 p.

    Research output: Contribution to journal › Article

    Open Access
    • 10 Scopus citations